ZIVO Bioscience, Inc. kicks off final phase of bovine mastitis study

[USA] ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that it has commenced work on the final, primary phase of its discovery-stage bovine mastitis efficacy study.

This latest efficacy trial is the final phase of a multi-phased validation effort that commenced in mid-2014. ZIVO and a global animal health company entered into an option/collaboration agreement in December of 2013 to determine if the Company’s bioactive compounds exhibit efficacy in addressing bovine mastitis, a common condition afflicting dairy cows that results in milk production losses, as well as analytics to isolate and characterize such bioactive compounds to the satisfaction of the collaborator.

Bovine mastitis is a global animal health issue affecting the world’s 244 million dairy cows and is responsible for billions of dollars in milk production losses.

This latest validation phase is complex in structure and execution, requiring a pre-pilot for pathogen cultivation, as well as a pilot test for initial inoculation and dose ranging. Once the preparatory work is completed and results are accepted by the Company’s collaborator, the balance of study moves forward to its conclusion. In addition to clinical observations, milk and blood samples, this final phase may include RNA extraction and gene expression analyses, which have the potential to create a significant trove of data to support the discovery-stage efficacy findings made by the Company.

 

View original article at: ZIVO Bioscience, Inc. kicks off final phase of bovine mastitis study

 

 

 

 

Leave a Reply